盐酸班布特罗在慢性阻塞性肺疾病急性加重期患者中的应用  

Application of bambuterol hydrochloride in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：张世通[1] 李维香 ZHANG Shi-tong;LI Wei-xiang(Department of Internal Medicine,Tianjin Jinnan District Station Hospital,Tianjin 300353,China;不详)

机构地区：[1]天津市津南区小站医院内科,天津300353 [2]天津市津南医院,天津300350

出　　处：《中国处方药》2024年第3期119-121,共3页Journal of China Prescription Drug

摘　　要：目的探讨盐酸班布特罗在慢性阻塞性肺疾病急性加重期患者中的应用。方法将2023年5月~2023年8月就诊的68例慢性阻塞性肺疾病急性加重期患者作为研究对象,按照随机数表法分为对照组及观察组。对照组34例进行盐酸莫西沙星治疗,观察组34例进行盐酸莫西沙星联合盐酸班布特罗治疗。比较两组患者临床疗效和不良反应情况,治疗前后的凝血功能指标水平。结果治疗前,对照组和观察组的凝血功能指标水平比较,差异无统计学意义(P>0.05);治疗后与同组治疗前相比,两组FIB、DD水平均明显降低,且与对照组相比,观察组明显更低(P<0.05),PT、TT、APTT水平均明显升高,且与对照组相比,观察组明显更高(P<0.05)。对照组的不良反应发生率为8.82%,观察组的不良反应发生率为17.65%,差异无统计学意义(P>0.05)。对照组和观察组的临床有效率分别为73.53%和94.12%,观察组明显更高(P<0.05)。结论盐酸班布特罗治疗可显著改善慢性阻塞性肺疾病急性加重期患者的凝血功能,进而提高治疗效果。Objective To investigate the application of bambuterol hydrochloride in patients with acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 68 patients with acute exacerbation of chronic obstructive pulmonary disease from May 2023 to August 2023 were divided into the control group and the observation group according to random number table method.The control group(34 cases)received moxifloxacin hydrochloride,and the observation group(34 cases)received moxifloxacin hydrochloride combined with bambuterol hydrochloride.The clinical efficacy and adverse reactions of the two groups were compared,and the levels of coagulation function indexes before and after treatment were compared.Results Before treatment,there was no significant difference in the level of coagulation function between the control group and the observation group(P>0.05).After treatment,FIB and DD levels in both groups were significantly lower than before treatment,and compared with the control group,the observation group was significantly lower(P<0.05),and PT,TT and APTT levels were significantly increased,and compared with the control group,the observation group was significantly higher(P<0.05).The incidence of adverse reactions was 8.82%in the control group and 17.65%in the observation group,the difference was not statistically significant(P>0.05).The clinical effective rate of the control group and the observation group were 73.53%and 94.12%,respectively,and the observation group was significantly higher(P<0.05).Conclusion The treatment of bambuterol hydrochloride can significantly improve the coagulation function of patients with acute exacerbation of chronic obstructive pulmonary disease,so as to improve the therapeutic effect.

关 键 词：慢性阻塞性肺疾病 盐酸班布特罗 凝血功能 临床疗效 

分 类 号：R972[医药卫生—药品] R563.9[医药卫生—药学]